When this was written — On 13 July 2026. The figures are as at that date or earlier and have not been updated since.
The stubborn short line
Short sellers targeting Clinuvel Pharmaceuticals (ASX: CUV) are refusing to clear their positions, even as the biopharma's share price mounts a steady recovery. The short position in the Melbourne-based developer currently sits at 9.15%, well clear of the peer sector average of 4.87%. This persistent short interest comes despite a 10.2% share price rally over the past three months, which accelerated into a 17.8% surge over the last 30 days to reach $10.27.
Typically, a double-digit monthly run-up triggers short covering as traders move to limit losses and protect capital. Instead, Clinuvel's price-short 30-day correlation has dropped to -0.005, indicating that short sellers are simply absorbing the upward price pressure. While peer biotechs have seen short positions dissolve under price pressure, the players shorting Clinuvel are digging in, holding their positions near the 90-day high of 9.48%. The 90-day average short position of 8.72% demonstrates that this is not a sudden spike, but a sustained campaign.
A cash fortress of scale
The primary obstacle for anyone betting against Clinuvel is the company's balance sheet, which resembles a defensive fortress. Half-year results for the period ending December 2025 revealed that cash reserves grew 4% to $232.99 million R1. This massive capital reserve provides a buffer against the broader market volatility that typically plagues capital-hungry biotech stocks.
While half-year revenue ticked up 4% to $36.93 million, net profit after tax declined 26% to $10.44 million R1. Management attributed this drop to aggressive strategic investments in its clinical pipeline rather than operational weakness R12. Clinuvel's financial independence is a rarity in the local life sciences sector, leading management to state that "cash is king" in turbulent macro environments 2. This financial cushion limits the risk of dilutive capital raises, which are the traditional trigger events for short-seller profits.
Smooth operations and zero catalysts
Short campaigns rely on negative operational catalysts—failed clinical trials, regulatory rejections, or executive departures. Clinuvel has given its opponents very little of this material. The company has maintained steady operational momentum across its key strategic programmes.
In late 2025, Clinuvel advanced its ACTH peptide portfolio, targeting a mid-2026 European filing for NEURACTHEL Instant 3. Simultaneously, the company has progressed its US expansion, filing its 20-F with the SEC and advancing its Level II ADR upgrade in preparation for a planned Nasdaq uplisting 456. To secure management continuity through this expansion phase, the board also finalised and confirmed the long-term employment terms for its chief executive officer 7. Without a clear operational misstep, the fundamental thesis for a heavy short position remains difficult to parse.
- 2025-08-28FY2025 revenue rises 8% to $95.02m[ref-8]
- 2025-12-01NEURACTHEL Instant EU filing targeted for mid-2026[ref-3]
- 2025-12-18US Level II ADR program and Nasdaq listing progress[ref-6]
- 2026-02-26H1 FY26 cash grows to $232.99m despite profit dip[ref-1]
- 2026-07-01CEO employment agreement terms finalized[ref-7]
The divergence in data
The lack of correlation between Clinuvel's rising share price and its stable short interest suggests a structural standoff. The short slope over the last 30 days is a negligible -0.0024% per day, and the 7-day slope is only slightly lower at -0.0349% per day. These figures show that short sellers are not actively fleeing the register.
With a cash balance exceeding $230 million, Clinuvel is insulated from the funding crises that short sellers usually exploit.
This flat trendline during a 17.8% monthly share price recovery indicates that short sellers are not trading the daily swings. Instead, they appear to be holding a long-term structural bet, ignoring the short-term pain of a rising share price. With ASIC's T+4 reporting delay, the current 9.15% figure reflects the state of play from last week, but the multi-month trend shows no signs of a short squeeze.
Whether this standoff breaks depends on whether Clinuvel can translate its massive cash reserves and clinical pipeline into accelerated earnings growth in the second half of the year. For now, both the buyers and the short sellers seem prepared to wait each other out.